Cargando…

Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis

MicroRNAs (miRNAs) are a class of small non-coding RNAs ranging from 17 to 25 nt in length. miR-637 is down-regulated in most cancers and up-regulated only in clear cell renal cell carcinoma (ccRCC). miR-637 can target 21 protein-coding genes, which are involved in the regulation of cell growth, cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Jinze, Liang, Chenhao, Su, Xinming, Wang, Qurui, Ke, Yufei, Fang, Jie, Zhang, Dayong, Duan, Shiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524011/
https://www.ncbi.nlm.nih.gov/pubmed/36175921
http://dx.doi.org/10.1186/s40364-022-00419-8
_version_ 1784800414096424960
author Shen, Jinze
Liang, Chenhao
Su, Xinming
Wang, Qurui
Ke, Yufei
Fang, Jie
Zhang, Dayong
Duan, Shiwei
author_facet Shen, Jinze
Liang, Chenhao
Su, Xinming
Wang, Qurui
Ke, Yufei
Fang, Jie
Zhang, Dayong
Duan, Shiwei
author_sort Shen, Jinze
collection PubMed
description MicroRNAs (miRNAs) are a class of small non-coding RNAs ranging from 17 to 25 nt in length. miR-637 is down-regulated in most cancers and up-regulated only in clear cell renal cell carcinoma (ccRCC). miR-637 can target 21 protein-coding genes, which are involved in the regulation of cell growth, cell cycle, cell proliferation, epithelial-mesenchymal transition (EMT), cancer cell invasion and metastasis, etc. In glioma, the transcription factor ZEB2 can bind to the miR-637 promoter region and inhibit miR-637 expression. Besides, miR-637 could be negatively regulated by competing endogenous RNA (ceRNAs) comprising 13 circular RNA (circRNAs) and 9 long non-coding RNA (lncRNAs). miR-637 is involved in regulating five signaling pathways, including the Jak/STAT3, Wnt/β-catenin, PI3K/AKT, and ERK signaling pathways. Low miR-637 expression was significantly associated with larger tumors and later tumor node metastasis (TNM) staging in cancer patients. Low miR-637 expression was also associated with poorer overall survival (OS) in cancer patients such as glioblastoma and low-grade gliomas (GBM/LGG), non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), and ovarian cancer (OV). Low expression of miR-637 increases the resistance of colorectal cancer (CRC) and human cholangiocarcinoma (CHOL) cancer cells to three anticancer chemotherapeutics (gemcitabine (dFdC), cisplatin (DDP), and oxaliplatin (OXA)). Our work summarizes the abnormal expression of miR-637 in various cancers, expounds on the ceRNA regulatory network and signaling pathway involved in miR-637, and summarizes the effect of its abnormal expression on the biological behavior of tumor cells. At the same time, the relationship between the expression levels of miR-637 and its related molecules and the prognosis and pathological characteristics of patients was further summarized. Finally, our work points out the insufficiency of miR-637 in current studies and is expected to provide potential clues for future miR-637-related studies.
format Online
Article
Text
id pubmed-9524011
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-95240112022-10-01 Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis Shen, Jinze Liang, Chenhao Su, Xinming Wang, Qurui Ke, Yufei Fang, Jie Zhang, Dayong Duan, Shiwei Biomark Res Review MicroRNAs (miRNAs) are a class of small non-coding RNAs ranging from 17 to 25 nt in length. miR-637 is down-regulated in most cancers and up-regulated only in clear cell renal cell carcinoma (ccRCC). miR-637 can target 21 protein-coding genes, which are involved in the regulation of cell growth, cell cycle, cell proliferation, epithelial-mesenchymal transition (EMT), cancer cell invasion and metastasis, etc. In glioma, the transcription factor ZEB2 can bind to the miR-637 promoter region and inhibit miR-637 expression. Besides, miR-637 could be negatively regulated by competing endogenous RNA (ceRNAs) comprising 13 circular RNA (circRNAs) and 9 long non-coding RNA (lncRNAs). miR-637 is involved in regulating five signaling pathways, including the Jak/STAT3, Wnt/β-catenin, PI3K/AKT, and ERK signaling pathways. Low miR-637 expression was significantly associated with larger tumors and later tumor node metastasis (TNM) staging in cancer patients. Low miR-637 expression was also associated with poorer overall survival (OS) in cancer patients such as glioblastoma and low-grade gliomas (GBM/LGG), non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), and ovarian cancer (OV). Low expression of miR-637 increases the resistance of colorectal cancer (CRC) and human cholangiocarcinoma (CHOL) cancer cells to three anticancer chemotherapeutics (gemcitabine (dFdC), cisplatin (DDP), and oxaliplatin (OXA)). Our work summarizes the abnormal expression of miR-637 in various cancers, expounds on the ceRNA regulatory network and signaling pathway involved in miR-637, and summarizes the effect of its abnormal expression on the biological behavior of tumor cells. At the same time, the relationship between the expression levels of miR-637 and its related molecules and the prognosis and pathological characteristics of patients was further summarized. Finally, our work points out the insufficiency of miR-637 in current studies and is expected to provide potential clues for future miR-637-related studies. BioMed Central 2022-09-30 /pmc/articles/PMC9524011/ /pubmed/36175921 http://dx.doi.org/10.1186/s40364-022-00419-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Shen, Jinze
Liang, Chenhao
Su, Xinming
Wang, Qurui
Ke, Yufei
Fang, Jie
Zhang, Dayong
Duan, Shiwei
Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis
title Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis
title_full Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis
title_fullStr Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis
title_full_unstemmed Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis
title_short Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis
title_sort dysfunction and cerna network of the tumor suppressor mir-637 in cancer development and prognosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524011/
https://www.ncbi.nlm.nih.gov/pubmed/36175921
http://dx.doi.org/10.1186/s40364-022-00419-8
work_keys_str_mv AT shenjinze dysfunctionandcernanetworkofthetumorsuppressormir637incancerdevelopmentandprognosis
AT liangchenhao dysfunctionandcernanetworkofthetumorsuppressormir637incancerdevelopmentandprognosis
AT suxinming dysfunctionandcernanetworkofthetumorsuppressormir637incancerdevelopmentandprognosis
AT wangqurui dysfunctionandcernanetworkofthetumorsuppressormir637incancerdevelopmentandprognosis
AT keyufei dysfunctionandcernanetworkofthetumorsuppressormir637incancerdevelopmentandprognosis
AT fangjie dysfunctionandcernanetworkofthetumorsuppressormir637incancerdevelopmentandprognosis
AT zhangdayong dysfunctionandcernanetworkofthetumorsuppressormir637incancerdevelopmentandprognosis
AT duanshiwei dysfunctionandcernanetworkofthetumorsuppressormir637incancerdevelopmentandprognosis